An experimental vaccine to protect against respiratory syncytial virus (RSV), a leading cause of illness and hospitalization among very young children, elicited high levels of RSV-specific antibodies when tested in animals, according to a report in the journal Science.
Related posts:
- Possible clues found to why HIV vaccine showed modest protection Insights into how the first vaccine ever reported to modestly prevent HIV infection in people might have worked were published online today in the New England Journal of Medicine. Scientists have found that among adults who received the experimental HIV vaccine during the landmark RV144 clinical trial, those who produced relatively high levels of a […]...
- Medicare Card, NIH-developed candidate dengue vaccine shows promise in early-stage trial Medicare Card, NIH-developed candidate dengue vaccine shows promise in early-stage trial...
- Medicare Card, NIH scientists map first steps in flu antibody development Medicare Card, NIH scientists map first steps in flu antibody development...
- Medicare Card, August is National Immunization Awareness Month Medicare Card, August is National Immunization Awareness Month...
- Medicare Card, NIH scientists shed light on mystery surrounding hepatitis B virus Medicare Card, NIH scientists shed light on mystery surrounding hepatitis B virus...
- Medicare Card: NIH-Supported Experimental Marburg Vaccine Prevents Disease Two Days after Infection An experimental vaccine developed to prevent outbreaks of Marburg hemorrhagic fever continues to show promise in monkeys as an emergency treatment for accidental exposures to the virus that causes the disease. There is no licensed treatment for Marburg infection, which has a high fatality rate....
- H1NI? Higher Dose of Seasonal Flu Vaccine Provides Extra Protection Higher Dose of Seasonal Flu Vaccine Provides Extra Protection ...
- Priming with DNA vaccine makes avian flu vaccine work better The immune response to an H5N1 avian influenza vaccine was greatly enhanced in healthy adults if they were first primed with a DNA vaccine expressing a gene for a key H5N1 protein, researchers say. Their report describes results from two clinical studies conducted by researchers from the National Institute of Allergy and Infectious Diseases (NIAID), […]...
- Medicare Card, NIH-funded study to test pneumococcal vaccine in older adults Medicare Card, NIH-funded study to test pneumococcal vaccine in older adults...
- Medicare, NIH scientists discover how dengue virus infects cells National Institutes of Health researchers have discovered a key step in how the dengue virus infects a cell. The discovery one day may lead to new drugs to prevent or treat the infection....
- NIH Scientists Advance Universal Flu Vaccine A universal influenza vaccine — so-called because it could potentially provide protection from all flu strains for decades — may become a reality because of research led by scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health....
- Medicare Card, Learn How to Prevent Lead Poisoning Medicare Card, Learn How to Prevent Lead Poisoning...
- 2009-2010 Influenza Season Week 43 ending October 31, 2009 During week 43 (October 25-31, 2009), influenza activity remained elevated in the U.S....
- Researchers show how anti-HIV drug acts to block herpes virus An anti-HIV drug also discovered to stop the spread of the genital herpes virus does so by disabling a key DNA enzyme of the herpes virus, according to findings by researchers at the National Institutes of Health and other institutions....
- Medicare Card, NIH researchers identify candidate drug to treat Batten disease Medicare Card, NIH researchers identify candidate drug to treat Batten disease...